Immupharma (IMM)

 

IMM Share PerformanceMore

52 week high70.32 17/02/17
52 week low23.00 26/02/16
52 week change 31.88 (132.81%)
4 week volume5,498,684 28/01/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 2167X Immupharma PLC 17 February 2017 17 FEBRUARY 2017 NOTIFICATION OF INTEREST BY LEGAL & GENERAL ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its...

Update on Lupuzor Phase III Study

RNS Number: 0128V Immupharma PLC 25 January 2017 25 JANUARY 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study Full Analysis of Patient Recruitment ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide further details of patient participation ...

Change of Adviser

RNS Number: 8943U Immupharma PLC 24 January 2017 24 JANUARY 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Change of Adviser ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to announce that it has appointed Northland Capital Partners as its Nominated Adviser and sole broker with im...

Holding(s) in Company

RNS Number: 9563S Immupharma PLC 29 December 2016 RNS: FOR IMMEDIATE RELEASE 29 DECEMBER 2016 ImmuPharma PLC ("ImmuPharma" or the "Company") TR1 NOTIFICATION OF MAJOR INTEREST ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Ca...

ImmuPharma completes Lupuzor patient recruitment

ImmuPharma has confirmed that patient recruitment has successfully been completed, on target, within the company's pi...

Update on Lupuzor Pivotal Phase III Study

RNS Number: 5353S Immupharma PLC 22 December 2016 RNS: FOR IMMEDIATE RELEASE 22 DECEMBER 2016 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study Patient Recruitment Completed ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to confirm tha...

ImmuPharma update on cancer compound

ImmuPharma has announced that Cancer Research, the prestigious medical journal of the American Association for Can...

Update on Cancer Compound IPP-204106 'Nucant'

RNS Number: 2696P Immupharma PLC 16 November 2016 RNS REACH: FOR IMMEDIATE RELEASE 16 NOVEMBER 2016 IMMUPHARMA PLC Update on Cancer Compound IPP-204106 'Nucant' Mechanism of Action Published in Prestigious Medical Journal 'Cancer Research' ImmuPharma plc (LSE:IMM) ("ImmuPharma" or the "Company" or the "Group")...

Fundamental DataMore

EPS-4.4
Dividend yield0 %

Latest discussion posts More

  • Price Movement

    What is going on here? Huge volume traded today and price rocketing early to 70 P. Looks like something big is going on and it has leaked out.
    17-Feb-2017
    Chrissp
  • I have high hopes here

    and having bought small in 30's and 40's p I am continuing to build a position out slowly here. I'm very comfortable buying in 50's, not least because I'm well up on current ...
    26-Jan-2017
    Nice to Michu
  • Lupuzor update

    "ImmuPharma has announced that it has been invited to open an additional site in Mauritius as part of its Phase III clinical trial of Lupuzor?, its lead programme for the ...
    7-Sep-2016
    Sambram

Users' HoldingsMore

Users who hold Immupharma also hold..
LLOYDS GRP.32%
BP19%
NATIONAL GRID14%
ROYAL BANK SCOT13%
GLAXOSMITHKLINE13%

Codes & Symbols

ISINGB0033711010
SymbolsIMM, LSE:IMM, IMM.L, IMM:LN, LON:IMM, XLON:IMM